Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
Targeted agents and immunotherapies have revolutionized cancer treatment, offering promising options for various cancer types. Unlike traditional therapies the principle of "more is better" is not always applicable to these new therapies due to their unique biomedical mechanisms. As a result, variou...
| Publicado en: | Clinical Trials Vol. 21; no. 3; pp. 298 - 308 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Sage Publications, Ltd.
Jun2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |